

WHO DRUG INFORMATION

Contents

General Policy Topics

Counterfeiting: an alliance of legitimate interests emerges 41

Reports on Individual Drugs

Chloramphenicol: no longer indicated for childhood meningitis? 45

Allopurinol: a new perspective in the treatment of cutaneous leishmaniasis 45

Oral rehydration therapy and hypernatraemia 46

Melarsoprol in trypanosomiasis: new insights into reactive encephalopathy 47

Zidovudine and survival 48

General Information

Tuberculosis and HIV infection 51

Pertussis vaccination: a national appraisal 52

Post-operative wound infections: the case for effective prophylaxis 53

Emerging resistance to group-A streptococci creates concern 55

Regulatory Matters

ACE inhibitors: warning on fetotoxicity reinforced 56

ACE inhibitors: anaphylactoid reactions noted in dialysis patients 56

Beta-adrenoreceptor agonists and asthma deaths 56

Bufexamac: hypersensitivity reactions 56

Cinchophen: an official seal of obsolescence 57

Corticosteroid products: warning regarding varicella 57

Extracts of germander: association with hepatitis 57

Glafenine: voluntary withdrawal 57

Illegal importation of unapproved medicines 57

Propofol: metabolic derangement following long-term use in children 58

Tacrine: cautious extension of clinical studies 58

Drugs for weight control: a radical reassessment 58

Zalcitabine: for monotherapy or combination treatment of HIV infection? 59

Essential Drugs

Diseases of the skin 60

Benzylpenicillin 67

Benzathine benzylpenicillin 67

Erythromycin 68

Mupirocin 68

Aciclovir 69

Tiabendazole 69

Methylrosanilinium chloride (gentian violet) 70

Neomycin + bacitracin 70

Calamine lotion 70

Aluminium diacetate 71

Podophyllum resin 71

Salicylic acid 71

Benzyl benzoate 72

Permethrin 72

Hydrocortisone 73

Epinephrine 73

Recent Publications

Drug surveillance: harmonizing regulatory requirements 75

Oral contraceptives and neoplasia 76

Proposed International Non-proprietary Names: List 67

79